Skip to main content

Advertisement

Fig. 6 | Journal of Translational Medicine

Fig. 6

From: Ruxolitinib/nilotinib cotreatment inhibits leukemia-propagating cells in Philadelphia chromosome-positive ALL

Fig. 6

Cotreatment with NL and RUX exhibited the most effective anti-LPC effect. LPCs sorted from newly diagnosed Ph+ALL patients (N = 6) were transplanted by IBMI into 5-week-old, sub-lethally irradiated (2.1 Gy of total body irradiation from a 60Co source) and anti-CD122-conditioned NOD/SCID mice. From +14 days post-transplantation, the recipient mice were randomly administered with vehicle (10% NMP-90% PEG 300), IM (100 mg/kg/day), NL (75 mg/kg/day), RUX (30 mg/kg/day), IM (100 mg/kg/day) combined with RUX (30 mg/kg/day), or NL (75 mg/kg/day) combined with RUX (30 mg/kg/day) via oral gavage for 14 days. a Representative images of splenomegaly in the mice under different treatment conditions and a control NOD/SCID mouse (Ctrl) without receiving the Ph+ALL LPCs transplantation. b Differences in human engraftment were further confirmed by HE staining (upper panels) and IHC with anti-hCD19 antibody labeling (lower panels) of the spleens in the recipient mice treated with the different drugs and the Ctrl mice. c The engraftment analysis of BCR/ABL-expressing BM cells using a TaqMan-based qRT-PCR assay in the recipient mice at 12 weeks post-transplant. d Representative western blots of phospho-CrkL, phospho-JAK2, and GAPDH in the bone marrow cells of humanized mice transplanted with Ph+ALL LPCs following treatment with vehicle, single agents or a combination of RUX and IM or NL mice, and Ctrl mice. All data from the independent experiments are presented as the mean ± SEM. Significance values: ***P < 0.0001

Back to article page